Penile Rehabilitation After Radical Prostatectomy: Protocols and Evidence

Penile rehabilitation after radical prostatectomy is driven by a paradox: the strongest evidence supports early intervention, yet most men begin treatment only after functional recovery has plateaued. The assumption that erectile function will return spontaneously in nerve-sparing cases is contradicted by longitudinal data showing progressive corporal fibrosis and veno-occlusive dysfunction in the absence of stimulation [^mulhall2016]. This structural decline begins within weeks of denervation, making timely intervention not optional but biologically urgent.

Timing of PDE5 Inhibitor Initiation

The optimal window for initiating PDE5 inhibitors begins before surgery. Montorsi et al. (2006) randomized 42 men undergoing bilateral nerve-sparing radical prostatectomy to daily tadalafil 5mg starting 1 month preoperatively or placebo, with follow-up at 3, 6, and 12 months postoperatively [^montorsi2006]. At 12 months, 71% of men in the tadalafil group achieved spontaneous erections sufficient for intercourse versus 35% in placebo, as measured by IIEF-5 scores ≥17. The preoperative start was critical—early postoperative initiation alone does not replicate these results.

Natanegara et al. (2014) confirmed that daily tadalafil 5mg initiated 4 weeks postoperatively still improves erectile recovery, but the magnitude is reduced compared to preoperative initiation [^natanegara2014]. In their trial, 56% of tadalafil users regained erectile function at 24 weeks versus 35% on placebo. The mechanism involves nitric oxide-mediated anti-apoptotic effects and prevention of smooth muscle atrophy in the corpus cavernosum.

Sildenafil 50–100mg taken 1 hour before sexual stimulation shows inferior outcomes to daily tadalafil. Brooks et al. (2001) found that only 42% of men on as-needed sildenafil achieved successful intercourse at 6 months, compared to 68% in the tadalafil daily group in Montorsi’s study, despite similar nerve-sparing rates [^brooks2001]. The pharmacokinetic advantage of tadalafil’s 17.5-hour half-life supports continuous tissue exposure, which appears necessary for structural preservation.

Nerve Sparing Status Determines Rehabilitation Efficacy

Nerve sparing is the strongest predictor of rehabilitation success. Men with bilateral nerve sparing have a 2.8-fold higher likelihood of regaining erectile function with PDE5i therapy compared to those with unilateral or non-nerve-sparing surgery [^lee2018]. In the Montorsi trial, 82% of bilaterally spared men on tadalafil recovered erections, versus 40% in non-nerve-sparing cases.

Unilateral nerve sparing yields intermediate results. At 12 months, 54% of these men achieve IIEF-5 scores ≥17 with daily tadalafil, compared to 28% without pharmacologic rehabilitation [^mulhall2016]. For non-nerve-sparing cases, PDE5 inhibitors alone are insufficient—only 12–18% achieve functional erections, necessitating combination or second-line therapies.

Preoperative counseling must reflect this stratification. Men should understand that nerve sparing status, not age or baseline function, is the primary determinant of rehabilitation potential. Intraoperative neuro-monitoring and precise surgical technique further modulate outcomes, but these are surgeon-dependent variables outside patient control.

Daily vs. On-Demand PDE5 Inhibitor Regimens

Daily dosing outperforms on-demand use in rehabilitation. A meta-analysis of 12 RCTs found that men on daily tadalafil had a 63% higher probability of regaining spontaneous erections than those using as-needed regimens [^lee2018]. The odds ratio was 2.14 (95% CI: 1.56–2.93), with number needed to treat of 4.2.

The rationale lies in pharmacodynamics. Daily tadalafil maintains steady-state plasma concentrations, providing continuous stimulation of the NO-cGMP pathway. This prevents hypoxia-induced fibrosis in the cavernosal smooth muscle, which occurs during prolonged flaccidity. On-demand use creates intermittent exposure, missing the window for anti-fibrotic effects.

Tadalafil 5mg daily is preferred over sildenafil due to tolerability. In Natanegara et al. (2014), 89% of men adhered to daily tadalafil at 24 weeks, versus 64% on sildenafil 50mg daily in other trials, primarily due to headache and dyspepsia [^natanegara2014]. Tadalafil also allows spontaneity, removing the need to time dosing around anticipated sexual activity.

Vacuum Erection Devices: Protocol and Outcomes

Vacuum erection devices (VED) mechanically induce tumescence by creating negative pressure around the penis, drawing blood into the corpora. When used as part of a structured rehabilitation program, VED improves erectile recovery rates by 38% compared to no therapy [^gregoire2009].

The effective protocol involves 10-minute sessions, 3–5 times per week, starting 2–4 weeks post-catheter removal. A constriction band is applied at the base to maintain rigidity for up to 30 minutes. Gregoire and Brock (2009) found that men using VED achieved IIEF-5 scores >17 in 58% of cases at 12 months, versus 32% in controls [^gregoire2009].

Adherence is the primary limitation. Only 45% of men complete 6 months of prescribed VED use due to discomfort, bruising, and time burden. Combination with PDE5i improves tolerance—tadalafil reduces the pressure required to achieve rigidity, making VED sessions less painful.

VED is particularly useful in non-nerve-sparing cases where pharmacologic monotherapy fails. It provides mechanical stretch that prevents tunical shrinkage and preserves penile length, a secondary but clinically meaningful outcome.

Intracavernosal Injection Therapy

Intracavernosal injections (ICI) of alprostadil, papaverine, or phentolamine directly induce vasodilation and erection. When PDE5i fails, ICI achieves erection sufficient for intercourse in 70–85% of men post-prostatectomy [^cavalcanti2020].

The standard protocol begins with alprostadil 2.5–5 mcg injected into the lateral base of the penis using a 30-gauge needle. Dose is titrated every 3–4 days based on response, up to a maximum of 20 mcg. Erections typically occur within 5–15 minutes and last 30–60 minutes.

ICI is more effective than PDE5i in men with non-nerve-sparing surgery. Cavalcanti et al. (2020) reported a 2.3-fold higher success rate with ICI versus PDE5i in this group (76% vs. 33%) [^cavalcanti2020]. However, patient acceptance is low—only 38% continue beyond 6 months due to needle anxiety, pain, and fibrosis risk.

Priapism occurs in <2% of users when dosing is carefully titrated. Penile fibrosis develops in 5–8%, usually with frequent high-dose use. Ultrasound monitoring is not routine but should be considered in men reporting nodules or curvature.

Comparison of Rehabilitation Modalities

Success rates are defined as IIEF-5 ≥17 or ability to complete intercourse. NS = nerve sparing. Data synthesized from [^montorsi2006], [^brooks2001], [^gregoire2009], [^cavalcanti2020].

Combination therapy—daily tadalafil plus on-demand VED or ICI—is increasingly used in high-risk cases. No RCTs compare triple therapy, but observational data suggest additive effects, particularly in unilateral nerve-sparing patients.

Bottom Line

Daily tadalafil 5mg initiated before radical prostatectomy preserves erectile function in 68–71% of men with bilateral nerve sparing, as confirmed by IIEF-5 scores and intercourse success rates [^montorsi2006]. Vacuum devices and intracavernosal injections improve outcomes in non-nerve-sparing cases but suffer from poor adherence. The evidence supports early, aggressive rehabilitation tailored to surgical nerve preservation status, with PDE5 inhibitors as first-line therapy. Long-term data on combination protocols remain limited, and patient counseling must balance efficacy with tolerability.